Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.

ABSTRACT:

Purpose of review

Bispecific antibodies combine antigen recognition sites from two or more antibodies into a single construct allowing simultaneous binding to multiple targets. Bispecific antibodies exist which can redirect immune effector cells against acute myeloid leukemia (AML) targets. This review will highlight the progress to date and the challenges in developing bispecific antibodies for the treatment of AML.

Recent findings

Currently, a number of bispecific antibody formats including bispecific T cell engagers, dual affinity retargeting proteins, and tandem diabodies are in clinical development for AML. These antibodies target antigens present on AML blasts, including CD33, and the low affinity IL3 receptor, CD123. T cell redirecting bispecific antibodies in early p

SUBMITTER: Guy DG 

PROVIDER: S-EPMC6295344 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature